» Articles » PMID: 29353208

Natural Products Berberine and Curcumin Exhibited Better Ameliorative Effects on Rats with Non-alcohol Fatty Liver Disease Than Lovastatin

Overview
Date 2018 Jan 22
PMID 29353208
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Studies have shown that satins and herbal products have potential to treat non-alcohol fatty liver disease (NAFLD) in clinic. However, no study has compared their effects, and their mechanisms remain unresolved. Here, we choose lovastatin and two herbal products including berberine and curcumin to compare their effects in treating NAFLD. NAFLD model was established by high fat food, and rats were administrated with lovastatin, berberine, curcumin, berberine + curcumin at the dosage of 100, 100, 100, 50 + 50 mg/kg bw, respectively. The body weight, visceral fat gain, histological inspection and serum parameters were studied to exam the curative effects. In addition, mediators including SREBP-1c, caveolin-1, pERK, NF-κB, TNF-α, and pJNK were studied. Results showed that berberine + curcumin group exhibited lower body and fat weigh compared with lovastatin group. Biochemical assays showed that LDL-c, ALT, AST, ALP, MDA, LSP level were lower in berberine + curcumin group compared with lovastatin group. Lower expression of SREBP-1c, pERK, TNF-α, and pJNK were also observed in berberine + curcumin group. We conclude that combination of curcumin and berberine exhibited better ameliorative effects in treating NAFLD than lovastatin, and this enhanced effect is associated with oxidative stress, hepatic inflammation and lipid metabolism.

Citing Articles

Exploring the role of curcumin in mitigating oxidative stress to alleviate lipid metabolism disorders.

Cheng M, Ding F, Li L, Dai C, Sun X, Xu J Front Pharmacol. 2025; 16:1517174.

PMID: 39950117 PMC: 11822302. DOI: 10.3389/fphar.2025.1517174.


Studying targeted oxidation in diabetic cognitive dysfunction based on scientometrics analysis: research progress of natural product approaches.

Tu W, Xu F, Li J, Tian X, Cao L, Wang L Front Endocrinol (Lausanne). 2025; 15():1445750.

PMID: 39758348 PMC: 11695123. DOI: 10.3389/fendo.2024.1445750.


The Possible Synergistic Pharmacological Effect of an Oral Berberine (BBR) and Curcumin (CUR) Complementary Therapy Alleviates Symptoms of Irritable Bowel Syndrome (IBS): Results from a Real-Life, Routine Clinical Practice Settings-Based Study.

Wade U, Pascual-Figal D, Rabbani F, Ernst M, Albert A, Janssens I Nutrients. 2024; 16(8).

PMID: 38674895 PMC: 11053504. DOI: 10.3390/nu16081204.


Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.

Ionita-Radu F, Patoni C, Nancoff A, Marin F, Gaman L, Bucurica A Int J Mol Sci. 2024; 25(8).

PMID: 38673787 PMC: 11050387. DOI: 10.3390/ijms25084201.


Curcumin-Based Fixed Dose Combination Products for Cholesterol Management: A Narrative Review.

Boretti A ACS Pharmacol Transl Sci. 2024; 7(2):300-308.

PMID: 38357288 PMC: 10863436. DOI: 10.1021/acsptsci.3c00234.